Abstract
The cannabinoid (CB1) receptor agonist HU-210 (0.5 mg/kg, i.v.) exhibited a pronounced antiarrhythmic effect in rats with the adrenaline (epinephrine) and aconitine induced arrhythmia models. At the same time, the intracerebrovascular introduction of HU-210 (500 or 5000 ng) did not affect the adrenaline-induced arrhythmia. The CB1 receptor pretreatment (blocking) with the SR 141716 antagonist (3 mg/kg) and the introduction of a ganglion blocker (hexamethonium, 10 mg/kg) did not inhibit the antiarrhythmic effect of HU-210. It is concluded that the antiarrhythmic effect of intravenously injected HU-210 is neither related to the CB 1 receptor activation nor mediated by the autonomous (vegetative) nervous system.
| Original language | English |
|---|---|
| Number of pages | 1 |
| Journal | Eksperimental'naya i Klinicheskaya Farmakologiya |
| Volume | 64 |
| Issue number | 3 |
| Publication status | Published - 1 Jan 2001 |
ASJC Scopus subject areas
- Toxicology
- Pharmacology
Fingerprint Dive into the research topics of 'Antiarrhythmic properties of the cannabinoid receptor agonist HU-210'. Together they form a unique fingerprint.
Cite this
Maslov, L. N., Lishmanov, Y. B., Maimeskulova, L. A., & Mechoulam, P. (2001). Antiarrhythmic properties of the cannabinoid receptor agonist HU-210. Eksperimental'naya i Klinicheskaya Farmakologiya, 64(3).